223 related articles for article (PubMed ID: 31674708)
1. Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.
Peak TC; Panigrahi GK; Praharaj PP; Su Y; Shi L; Chyr J; Rivera-Chávez J; Flores-Bocanegra L; Singh R; Vander Griend DJ; Oberlies NH; Kerr BA; Hemal A; Bitting RL; Deep G
Mol Carcinog; 2020 Jan; 59(1):62-72. PubMed ID: 31674708
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
3. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy.
Jiang W; Chen J; Gong C; Wang Y; Gao Y; Yuan Y
J Nanobiotechnology; 2020 Mar; 18(1):50. PubMed ID: 32188463
[TBL] [Abstract][Full Text] [Related]
4. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
[TBL] [Abstract][Full Text] [Related]
5. [Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles].
Guan H; Ling ZX; Fang F; Mao LK; You ZH; Wang C; Chen SQ; Xu B; Chen M
Zhonghua Nan Ke Xue; 2018 Feb; 24(2):116-121. PubMed ID: 30156069
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
Kim J; Park S; Kim S; Ryu S; Hwang H; Cho S; Han Y; Kim J; Park Y; Lee EK; Lee M
Prostate; 2024 Jun; 84(9):814-822. PubMed ID: 38558458
[TBL] [Abstract][Full Text] [Related]
7. Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies.
Liang Y; Jeganathan S; Marastoni S; Sharp A; Figueiredo I; Marcellus R; Mawson A; Shalev Z; Pesic A; Sweet J; Guo H; Uehling D; Gurel B; Neeb A; He HH; Montgomery B; Koritzinsky M; Oakes S; de Bono JS; Gleave M; Zoubeidi A; Wouters BG; Joshua AM
Clin Cancer Res; 2021 Apr; 27(8):2340-2351. PubMed ID: 33542074
[TBL] [Abstract][Full Text] [Related]
8. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z
Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075
[TBL] [Abstract][Full Text] [Related]
9. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
12. miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.
Wang ZC; Li Y; Wang KL; Wang L; You BS; Zhao DF; Liu ZQ; Fang RZ; Wang JQ; Zhang W; Zhang JM; Xu WH
Aging (Albany NY); 2020 Jul; 12(14):14418-14433. PubMed ID: 32694237
[TBL] [Abstract][Full Text] [Related]
13. Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression.
Wu G; Sun Y; Xiang Z; Wang K; Liu B; Xiao G; Niu Y; Wu D; Chang C
Cell Death Dis; 2019 Jan; 10(2):37. PubMed ID: 30674872
[TBL] [Abstract][Full Text] [Related]
14. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
15. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
[TBL] [Abstract][Full Text] [Related]
16. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H
Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942
[TBL] [Abstract][Full Text] [Related]
17. Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3'-diindolylmethane in an enzalutamide-resistant prostate cancer cell line.
Tsao CW; Li JS; Lin YW; Wu ST; Cha TL; Liu CY
Sci Rep; 2021 Jan; 11(1):1239. PubMed ID: 33441906
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H
Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682
[TBL] [Abstract][Full Text] [Related]
19. Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.
Ware KE; Somarelli JA; Schaeffer D; Li J; Zhang T; Park S; Patierno SR; Freedman J; Foo WC; Garcia-Blanco MA; Armstrong AJ
Oncotarget; 2016 Aug; 7(31):50507-50521. PubMed ID: 27409172
[TBL] [Abstract][Full Text] [Related]
20. The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer.
Liu B; Sun Y; Tang M; Liang C; Huang CP; Niu Y; Wang Z; Chang C
Cell Death Dis; 2020 Sep; 11(9):807. PubMed ID: 32978369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]